Zhongsheng Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for ciclosporin eye drops and compound topicamide eye drops approved and issued by the State Drug Administration. Cyclosporine eye drops are clinically used to treat severe spring keratitis in children and adolescents aged 4 years and above. Compound topicamide eye drops are clinically used to dilate pupils and control paralysis for the purpose of diagnosis and treatment. Obtaining the “Drug Registration Certificate” this time is beneficial to enhancing the company's market competitiveness and is expected to have a positive impact on the company's future performance.

Zhongsheng Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for ciclosporin eye drops and compound topicamide eye drops approved and issued by the State Drug Administration. Cyclosporine eye drops are clinically used to treat severe spring keratitis in children and adolescents aged 4 years and above. Compound topicamide eye drops are clinically used to dilate pupils and control paralysis for the purpose of diagnosis and treatment. Obtaining the “Drug Registration Certificate” this time is beneficial to enhancing the company's market competitiveness and is expected to have a positive impact on the company's future performance.